Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19 : REMAP-CAP randomized controlled trial

Y. M. Arabi, A. C. Gordon, L. P. G. Derde, A.D. Nichol, S. Murthy, F. A. Beidh, D. Annane, L. A. Swaidan, A. Beane, R. Beasley, L. R. Berry, Z. Bhimani, M. J. M. Bonten, C. A. Bradbury, F. M. Brunkhorst, M. Buxton, A. Buzgau, A. Cheng, M. De Jong, M. A. DetryE. J. Duffy, L. J. Estcourt, M. Fitzgerald, R. Fowler, T. D. Girard, E. C. Goligher, H. Goossens, R. Haniffa, A. M. Higgins, T. E. Hills, C. M. Horvat, D. T. Huang, A. J. King, F. Lamontagne, P. R. Lawler, R. Lewis, K. Linstrum, E. Litton, E. Lorenzi, S. Malakouti, D. F. McAuley, A. McGlothlin, S. Mcguinness, B. J. McVerry, S. K. Montgomery, S. C. Morpeth, P. R. Mouncey, K. Orr, R. Parke, I. Gosbell, et al.

Research output: Contribution to journal › Article › peer-review

73 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19 : REMAP-CAP randomized controlled trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science